Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 216

Sort by

Sort Order Select

Journal Articles

Chromoplexy and Chromothripsis Are Important Prognostically in Myeloma and Deregulate Gene Function By a Range of Mechanisms

Cody Ashby, PhD, Eileen M Boyle, MD MSc, Brian A Walker, PhD, Michael A Bauer, PhD, Katie Rose Ryan, PhD, Judith Dent, Anjan Thakurta, Erin Flynt, Faith E. Davies, MD, Gareth Morgan, MD PhD

Blood (2019) 134 (Supplement_1): 3767.

https://doi.org/10.1182/blood-2019-130335

Published: 2019

Journal Articles

Simultaneous Kinase Inhibition with Ibrutinib and BCL2 Inhibition with Venetoclax As a Therapeutic Strategy for Acute Lymphoblastic Leukemia

Christopher A. Eide, Stephen E Kurtz, PhD, Andy Kaempf, MS, Nicola Long, Jessica Leonard, MD, Bill H. Chang, MD PhD, Motomi Mori, PhD, Brian J. Druker, Jeffrey W. Tyner

Blood (2019) 134 (Supplement_1): 3950.

https://doi.org/10.1182/blood-2019-131288

Published: 2019

Journal Articles

First-in-Human Study of Abbv-621, a TRAIL Receptor Agonist Fusion Protein, in Patients (Pts) with Relapsed/Refractory (RR) Acute Myeloid Leukemia (AML) and Diffuse Large B-Cell Lymphoma (DLBCL)

Maja J.A. de Jonge, MD, Benedito A. Carneiro, MD, Lot Devriese, MD PhD, Toshihiko Doi, MD PhD, Sudhir Penugonda, MD MPH, Adam M. Petrich, MD, Silpa Nuthalapati, PhD, Monica Motwani, PhD, Dimple A. Modi, PhD, Yu-Wei Chang, PhD, Emiliano Calvo, MD PhD, Victor Moreno, MD PhD

Blood (2019) 134 (Supplement_1): 3924.

https://doi.org/10.1182/blood-2019-129783

Published: 2019

Journal Articles

Economic Burden of Disease Progression Among Transplant Eligible Multiple Myeloma Patients Who Have Received at Least One Line of Therapy in the US

Rafael Fonseca, MD, May Hagiwara, PhD, Sumeet Panjabi, PhD, Emre Yucel, PhD MSc, MBA, BSPharm, Jacqueline Buchanan, Thomas Delea, MBA

Blood (2019) 134 (Supplement_1): 2211.

https://doi.org/10.1182/blood-2019-123743

Published: 2019

Journal Articles

Longitudinal Changes in the Intestinal Microbiome Composition Following Gut Decontamination in Pediatric Allogeneic Hematopoietic Stem Cell Transplant Patients: A Pilot Study

Christopher Severyn, MD PhD, Wendy B. London, PhD, Paige Kao, MPH, Sophie Silverstein, BS, Michelle Li, BS, Soomin Kim, BA, Kelly Verrill, BSN, Jerome Ritz, MD, Ami S. Bhatt, MD PhD, Jennifer Whangbo, MD PhD

Blood (2019) 134 (Supplement_1): 5665.

https://doi.org/10.1182/blood-2019-122480

Published: 2019

Journal Articles

Identification of Deubiquitinase OTUD1 As a Novel Player in Resistance of Multiple Myeloma to Bortezomib

Alexander Vdovin, Tomas Jelinek, MD, Matous Hrdinka, PhD, Juli R. Bago, PhD, Tereza Sevcikova, Roman Hajek, Prof, MD PhD, Michal Simicek, PhD

Blood (2019) 134 (Supplement_1): 5526.

https://doi.org/10.1182/blood-2019-127930

Published: 2019

Journal Articles

Outcomes of Patients with T-Lymphoblastic Lymphoma Undergoing Allogeneic Stem Cell Transplantation: Retrospective Results from a Single Center

Amandeep Salhotra, MD, Liana Nikolaenko, MD, Lu Chen, PhD, Ni-Chun Tsai, PhD, Diane Lynne Smith, PhD, Auayporn P. Nademanee, MDBS, Leslie L. Popplewell, MD FRCPA, Alex F. Herrera, MD, Matthew Mei, MD, Ibrahim Aldoss, MD, Vinod A. Pullarkat, MD, Stephen J. Forman, MD, Jasmine M. Zain, MD

Blood (2019) 134 (Supplement_1): 5729.

https://doi.org/10.1182/blood-2019-131437

Published: 2019

Journal Articles

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Commonly Presents in the Setting of Prior or Concomitant Hematologic Malignancies (PCHM): Patient Characteristics and Outcomes in the Rapidly Evolving Modern Targeted Therapy Era

Naveen Pemmaraju, MD, Hagop M. Kantarjian, MD, Joseph D. Khoury, MD, Sanam Loghavi, MD, Susan O'Brien, MD, Jorge E. Cortes, MD, Guillermo Garcia-Manero, MD, Elias Jabbour, MD, Srdan Verstovsek, MD PhD, Nitin Jain, MD, Madeline Duvic, MD, Phyu Aung, MD, C. Cameron Yin, MD PhD, Sergej Konoplev, Keyur P. Patel, MBBS, PhD, Sherry A. Pierce, BSN, BA, Hannah Beird, PhD, Muzaffar H. Qazilbash, MD, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 2723.

https://doi.org/10.1182/blood-2019-132185

Published: 2019

Journal Articles

Higher Stability of Mutant IDH1/2 mRNA As Compared to Wild-Type mRNA in Patients with Acute Myeloid Leukemia

Maher Albitar, MD, Marina Y Konopleva, MD PhD, Ivan De Dios, BS, Jeffrey Justin Estella, BS, MS, Spiraggelos Antzoulatos, Steven M. Kornblau, MD, Antonio Cavazos, Sanam Loghavi, MD, Koichi Takahashi, MD, Hagop M. Kantarjian, MD, Courtney D. DiNardo, MDMSc

Blood (2019) 134 (Supplement_1): 2730.

https://doi.org/10.1182/blood-2019-127383

Published: 2019

Journal Articles

Patient-Level Meta-Analysis of End-of-Therapy PET-CR as a Surrogate Endpoint for PFS and OS in Patients with Previously Untreated DLBCL: Implications for Clinical Trial Design

Donald Berry, PhD, Kristine Broglio, MS, Carol Ward, MSc, Federico Mattiello, PhD, Deniz Sahin, BSc, Tina G Nielsen, MD PhD, Anna McGlothlin, PhD, Corrine Elliott, MS, Thomas E. Witzig, MD, Laurie H Sehn, MD, Marek Trněný, MD, Umberto Vitolo, Maurizio Martelli, MD, Lale Kostakoglu, MD MPH, Grzegorz Nowakowski, MD

Blood (2019) 134 (Supplement_1): 4101.

https://doi.org/10.1182/blood-2019-124067

Published: 2019

Journal Articles

High Dependence on Medicare and Foundation Grant Assistance Among Patients with Hematologic Malignancies Receiving Novel Oral Therapeutics

Erlene K. Seymour, MD, Lucius Daniel, Eva Pointer, MS, Stephen T. Smith, Charles A. Schiffer, MD

Blood (2019) 134 (Supplement_1): 64.

https://doi.org/10.1182/blood-2019-128905

Published: 2019

Journal Articles

Optimization of Tacrolimus Serum Levels When Combined with Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Hematopoietic Cell Transplantation: Outcome Data Analysis

Janny M. Yao, PharmD, Dongyun Yang, PhD, Saloomeh Mokhtari, Amandeep Salhotra, MD, Haris Ali, MD, Shukaib Arslan, MD, Salman Otoukesh, MD, Ibrahim Aldoss, MD, Karamjeet S. Sandhu, MD, Anthony Stein, MD, David Snyder, MD, Vinod A. Pullarkat, MD, Guido Marcucci, MD, Stephen J Forman, MD, Ryotaro Nakamura, MD, Monzr M. Al Malki, MD

Blood (2019) 134 (Supplement_1): 4518.

https://doi.org/10.1182/blood-2019-129221

Published: 2019

Journal Articles

Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined Analysis of the STORM and Mammoth Studies

Blood (2019) 134 (Supplement_1): 3125.

https://doi.org/10.1182/blood-2019-124991

Published: 2019

Journal Articles

Long-Term Outcome of Total Therapy Regimens: Impact of Molecular Subgroups

Frits van Rhee, MD PhD, Maurizio Zangari, MD, Carolina D. Schinke, MD, Guido J. Tricot, MD PhD, Doug Steward, Susan Panozzo, Jeffery R. Sawyer, Brian A Walker, PhD, Joshua Epstein, DSc, Faith E. Davies, MD, Gareth Morgan, MD PhD, Adam Rosenthal, MS, Antje Hoering, PhD, Katherine K Nishimura, Bart Barlogie, MD PhD

Blood (2019) 134 (Supplement_1): 3309.

https://doi.org/10.1182/blood-2019-131870

Published: 2019

Journal Articles

Title - Myeloma XI Trial for Newly Diagnosed Multiple Myeloma (NDMM); Long Term Second Primary Malignancy (SPM) Incidence in the Context of Lenalidomide Maintenance

John R Jones, MD, David Cairns, MSc, PhD, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Faith E. Davies, MD, Rachel Sigsworth, Matthew Jenner, MBBS, MRCP, FRCPath, Martin F. Kaiser, Rebecca Mottram, BA, BSc, Mark T Drayson, MB ChB, PhD FRCPath, Gordon Cook, Walter M Gregory, PhD, Roger G. Owen, MD, Kevin Boyd, MB BS, BSc, MRCP, FRCPath, PhD, Graham Jackson, MA, MB BS, FRCP, FRCPath, MD, Gareth Morgan, MDPhDFRCP

Blood (2019) 134 (Supplement_1): 3132.

https://doi.org/10.1182/blood-2019-127469

Published: 2019

Journal Articles

Daratumumab (DARA) Subcutaneous (SC) Delivery in Relapsed or Refractory Multiple Myeloma (RRMM): Population Pharmacokinetics (PPK) and Exposure-Response (E-R) Analysis

Melody Luo, PhD, Dolly A. Parasrampuria, PhD, Saad Z. Usmani, MD, Maria-Victoria Mateos, Hareth Nahi, MD PhD, Christoph Heuck, Ming Qi, MD PhD, Steven Sun, Pamela L. Clemens, PhD, Honghui Zhou, Yu-Nien (Tom) Sun, PhD, Steven Xu, PhD

Blood (2019) 134 (Supplement_1): 3151.

https://doi.org/10.1182/blood-2019-123405

Published: 2019

Journal Articles

OP201: A Phase 1/2 Study of Melflufen and Dexamethasone in Patients with Immunoglobulin Light Chain (AL) Amyloidosis

Giovanni Palladini, MD PhD, Stefan O. Schönland, MD, Suzanne Lentzsch, MD PhD, M. Teresa Cibeira, MD PhD, Roman Hajek, Prof, MD PhD, Arnaud Jaccard, MD PhD, Krzysztof Jamroziak, MD PhD, Eftathios Kastritis, Vaishali Sanchorawala, MD, Fredrik H. Schjesvold, MD PhD, Ashutosh D Wechalekar, MBBS, MD FRCP, FRCPath, DM, Sara Thuresson, MSc, Johan Harmenberg, MD PhD, Catriona Byrne, RN, Giampaolo Merlini, MD

Blood (2019) 134 (Supplement_1): 3163.

https://doi.org/10.1182/blood-2019-124244

Published: 2019

Journal Articles

Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the First Interim Analysis of the Phase 2 EMN12/HOVON129 Study

Blood (2019) 134 (Supplement_1): 693.

https://doi.org/10.1182/blood-2019-125120

Published: 2019

Journal Articles

Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update

Blood (2019) 134 (Supplement_1): 691.

https://doi.org/10.1182/blood-2019-123465

Published: 2019

Journal Articles

Outcomes of Transplant-Eligible Newly Diagnosed Ultra-High Risk Myeloma Patients Treated in the NCRI Myeloma XI Trial Indicate the Need for Early Treatment Stratification and Novel Treatment Approaches

Martin F. Kaiser, Matthew Jenner, MBBS, MRCP, FRCPath, David Cairns, MSc, PhD, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Andrea Paterson, Rebecca Mottram, BA, BSc, Faith E. Davies, MD, Mark T Drayson, MB ChB, PhD FRCPath, Roger G. Owen, MD, Gareth Morgan, MDPhDFRCP, Gordon Cook, Graham Jackson, MA, MB BS, FRCP, FRCPath, MD

Blood (2019) 134 (Supplement_1): 604.

https://doi.org/10.1182/blood-2019-124819

Published: 2019

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Chromoplexy and Chromothripsis Are Important Prognostically in Myeloma and Deregulate Gene Function By a Range of Mechanisms

Simultaneous Kinase Inhibition with Ibrutinib and BCL2 Inhibition with Venetoclax As a Therapeutic Strategy for Acute Lymphoblastic Leukemia

First-in-Human Study of Abbv-621, a TRAIL Receptor Agonist Fusion Protein, in Patients (Pts) with Relapsed/Refractory (RR) Acute Myeloid Leukemia (AML) and Diffuse Large B-Cell Lymphoma (DLBCL)

Economic Burden of Disease Progression Among Transplant Eligible Multiple Myeloma Patients Who Have Received at Least One Line of Therapy in the US

Longitudinal Changes in the Intestinal Microbiome Composition Following Gut Decontamination in Pediatric Allogeneic Hematopoietic Stem Cell Transplant Patients: A Pilot Study

Identification of Deubiquitinase OTUD1 As a Novel Player in Resistance of Multiple Myeloma to Bortezomib

Outcomes of Patients with T-Lymphoblastic Lymphoma Undergoing Allogeneic Stem Cell Transplantation: Retrospective Results from a Single Center

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Commonly Presents in the Setting of Prior or Concomitant Hematologic Malignancies (PCHM): Patient Characteristics and Outcomes in the Rapidly Evolving Modern Targeted Therapy Era

Higher Stability of Mutant IDH1/2 mRNA As Compared to Wild-Type mRNA in Patients with Acute Myeloid Leukemia

Patient-Level Meta-Analysis of End-of-Therapy PET-CR as a Surrogate Endpoint for PFS and OS in Patients with Previously Untreated DLBCL: Implications for Clinical Trial Design

High Dependence on Medicare and Foundation Grant Assistance Among Patients with Hematologic Malignancies Receiving Novel Oral Therapeutics

Optimization of Tacrolimus Serum Levels When Combined with Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Hematopoietic Cell Transplantation: Outcome Data Analysis

Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined Analysis of the STORM and Mammoth Studies

Long-Term Outcome of Total Therapy Regimens: Impact of Molecular Subgroups

Title - Myeloma XI Trial for Newly Diagnosed Multiple Myeloma (NDMM); Long Term Second Primary Malignancy (SPM) Incidence in the Context of Lenalidomide Maintenance

Daratumumab (DARA) Subcutaneous (SC) Delivery in Relapsed or Refractory Multiple Myeloma (RRMM): Population Pharmacokinetics (PPK) and Exposure-Response (E-R) Analysis

OP201: A Phase 1/2 Study of Melflufen and Dexamethasone in Patients with Immunoglobulin Light Chain (AL) Amyloidosis

Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the First Interim Analysis of the Phase 2 EMN12/HOVON129 Study

Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update

Outcomes of Transplant-Eligible Newly Diagnosed Ultra-High Risk Myeloma Patients Treated in the NCRI Myeloma XI Trial Indicate the Need for Early Treatment Stratification and Novel Treatment Approaches

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only